AQUIPTA Approved
2026-11-16 06:00:49

AbbVie Receives Approval for Acute Migraine Treatment, AQUIPTA, in Japan

AbbVie Receives Approval for AQUIPTA in Japan



AbbVie, a global biopharmaceutical company, recently announced that it has obtained approval for its migraine treatment, AQUIPTA (atogepant), in Japan. This approval comes as a significant development as it allows the use of AQUIPTA as an acute treatment option for migraine attacks in adults, expanding the range of available therapies for this debilitating condition.

Understanding Migraine and its Impact


According to recent statistics, approximately 8.4% of the population in Japan suffers from migraines. This common neurological disorder significantly affects daily life, leading to decreased productivity at work and limitations in social activities due to the debilitating symptoms experienced by patients. Migraines can cause moderate-to-severe throbbing pain, often localized to one side of the head and accompanied by nausea, vomiting, and sensitivities to light and sound. Without appropriate treatment, migraine attacks can last anywhere from four hours to three days, making it difficult for sufferers to engage in their regular activities.

Migraine is a global health issue, impacting over a billion people around the world. It disproportionally affects women under the age of 50, making it a leading cause of disability and socio-economic burden. Unmanaged, migraines can lead to substantial economic losses, with the burden in Japan equating to an estimated 1.23% of its GDP as of 2021.

About AQUIPTA


AQUIPTA, a CGRP receptor antagonist, targets pathways involved in migraines, offering an oral solution for acute treatment and prevention of migraine attacks. Uniquely, during an acute phase, patients typically take a dosage of 60mg when experiencing a migraine. For preventive measures, a daily dosage of 60mg is recommended. Approval was based on the outcomes from an international Phase 3 clinical trial that predominantly focused on adult migraine patients, showcasing AQUIPTA’s potential to alleviate the migraine burden effectively.

Commenting on the Approval


Thiago Campos Rodriguez, President of AbbVie Japan, expressed optimism regarding the approval, stating that it marks a significant step forward for many patients suffering from migraines. The introduction of a new oral treatment option is expected to enhance patients' health and quality of life while lessening the social burden imposed by migraines.

The Broader Picture of Migraine


The ongoing burden of migraines highlights the need for effective treatment options. Despite existing therapies, the overall burden of migraines has remained stagnant over the past decade, underscoring the importance of developing novel treatments like AQUIPTA. As healthcare professionals continue to seek ways to manage symptoms effectively, AbbVie is committed to supporting patients facing the challenges of migraine through innovative research and collaborations.

In summary, AbbVie's AQUIPTA offers a promising avenue for patients suffering from migraines, addressing both the immediate acute phases and ongoing management of migraine attacks. This approval not only enhances treatment landscapes in Japan but also amplifies awareness regarding the implications of migraines on daily life. As continued research develops, such advancements play a crucial role in mitigating pain and improving the overall well-being of countless individuals.

For more information about AbbVie and its dedication to addressing serious health challenges, visit AbbVie’s website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.